Mergers & Acquisitions ·
On June 22, 2026, AbbVie Inc. and Apogee Therapeutics, Inc. announced a definitive agreement for AbbVie to acquire…
ABBVAbbVie Inc.
On June 22, 2026, AbbVie Inc. and Apogee Therapeutics, Inc. announced a definitive agreement for AbbVie to acquire Apogee. The transaction is expected to be accretive to AbbVie's adjusted diluted earnings per share beginning in 2032. The acquisition includes Apogee's pipeline assets, specifically zumilokibart (APG777) and APG273. AbbVie operates in the biopharmaceutical industry, developing and marketing advanced therapies for complex health conditions.